ADA Scientific Sessions 2026 Abstract

Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HDM1002) in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Diet and Exercise or Metformin

By Yiming Mu, Qi Ni, Qingju Li, Junfang Xu

Trial in peopleInterventions

The paper

Yiming Mu, Qi Ni, Qingju Li, Junfang Xu

Beijing

ADA Scientific Sessions 2026 Abstract, 6 Jun 2026

Presented at ADA Scientific Sessions 2026, oral 1218-OR

doi.org/10.2337/db26-1218-or

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes